.@ScottGottliebMD at a #postlive event on AI medical devices: imaging apps are here but applying AI broadly (like in clinical trials) further away from a reg standpoint 
On precision medicine: lots of Qs that need to be answered. Can’t answer those in “reasonably sized” clinical trials so FDA allowing approval based on small trials. Need for robust post market follow up
.@SGottliebFDA on the Post’s story re: Pfizer not publishing data on Enbrel and Alzheimer’s
Says there wasn’t a need to publish the research. Already known anti inflammatories didn’t have large effect
“Damned if you do, damned if you don’t”
Says there wasn’t a need to publish the research. Already known anti inflammatories didn’t have large effect
“Damned if you do, damned if you don’t”
A little side note that’s unrelated: Gottlieb notes earlier he’s worked with Pfizer in the last and “I’ll be working with them most likely in the future”
.@ScottGottliebMD on fentanyl and opioid crisis: getting prescribing #s down and keeping them down important but we must look at imports and seizures on the border—that’s where lots of problems now happening
“The growth in seizures dwarfed the decline in medical prescribing”
“The growth in seizures dwarfed the decline in medical prescribing”
• • •
Missing some Tweet in this thread? You can try to
force a refresh
